REFERENCES Cell cycle control and cancer

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science
1994;266:1821–1828.
2. Sanchez I, Dynlacht BD. New insights into cyclins, CDKs, and cell
cycle control. Semin Cell Dev Biol 2005;16:311–321.
3. Sherr CJ. Cancer cell cycles. Science 1996;274:1672–1677.
4. Hartley KO, Gell D, Smith GC, et al. DNA-dependent protein kinase
catalytic subunit: a relative of phosphatidylinositol 3-kinase and the
ataxia telangiectasia gene product. Cell 1995;82:849–856.
5. Radford IR. p53 status, DNA double-strand break repair proficiency,
and radiation response of mouse lymphoid and myeloid cell lines. Int J
Radiat Biol 1994;66:557–560.
6. Radford IR, Murphy TK. Radiation response of mouse lymphoid and
myeloid cell lines. Part III. Different signals can lead to apoptosis and
may influence sensitivity to killing by DNA double-strand breakage.
Int J Radiat Biol 1994;65:229–239.
7. Warters RL, Lyons BW. Variation in radiation-induced formation
of DNA double-strand breaks as a function of chromatin structure.
Radiat Res 1992;130:309–318.
8. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM
and ATM-dependent signaling pathways. DNA Repair (Amst) 2004;3:
889–900.
9. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, et al. ATM activation in
normal human tissues and testicular cancer. Cell Cycle 2005;4:838–845.
10. Samuel T, Weber HO, Funk JO. Linking DNA damage to cell cycle
checkpoints. Cell Cycle 2002;1:162–168.
11. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by
ATM in response to DNA damage. Science 1998;281:1674–1677.
12. Canman CE, Lim DS. The role of ATM in DNA damage responses
and cancer. Oncogene 1998;17:3301–3308.
13. Stracker TH, Theunissen JW, Morales M, et al. The Mre11 complex and
the metabolism of chromosome breaks: the importance of communicating
and holding things together. DNA Repair (Amst) 2004;3:845–854.
14. Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex
for ATM activation by DNA damage. Embo J 2003;22:5612–5621.
15. Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage.
Cancer Res 1995;55:5991–6001.
16. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage.
Curr Opin Genet Dev 2001;11:71–77.
17. Kastan M. Ataxia-telangiectasia—broad implications for a rare disorder.
N Engl J Med 1995;333:662–663.
18. Hoekstra MF. Responses to DNA damage and regulation of cell cycle
checkpoints by the ATM protein kinase family. Curr Opin Genet Dev
1997;7:170–175.
19. Barzilai A, Yamamoto K. DNA damage responses to oxidative stress.
DNA Repair (Amst) 2004;3:1109–1115.
20. Abraham RT. Checkpoint signaling: epigenetic events sound the DNA
strand-breaks alarm to the ATM protein kinase. Bioessays 2003;25:
627–630.
21. Amundson SA, Bittner M, Fornace AJ Jr. Functional genomics as a
window on radiation stress signaling. Oncogene 2003;22:5828–5833.
22. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling
pathways and their organization in space and time. DNA Repair
(Amst) 2004;3:997–1007.
23. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response
to DNA damage. Curr Opin Cell Biol 2001;13:738–747.
24. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the
DNA damage sensor responsible for activating p53-dependent G1 arrest.
Proc Natl Acad Sci U S A 1996;93:4827–4832.
25. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest
over multiple cell cycles in response to gamma-irradiation. Cancer Res
1997;57:1171–1179.
26. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced
cell cycle arrest compromised by p21 deficiency. Nature 1995;377:
552–557.
27. Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo
normal development, but are defective in G1 checkpoint control.
Cell 1995;82:675–684.
28. Bernhard EJ, McKenna WG, Muschel RJ. Radiosensitivity and the cell
cycle. Cancer J Sci Am 1999;5:194–204.
29. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2
checkpoint function in cancer cells with disrupted p53. J Natl Cancer
Inst 1996;88:956–965.
30. Bernhard EJ, Maity A, Muschel RJ, et al. Effects of ionizing radiation on
cell cycle progression. A review. Radiat Environ Biophys 1995;34:79–83.
31. Costanzo V, Robertson K, Ying CY, et al. Reconstitution of an ATMdependent
checkpoint that inhibits chromosomal DNA replication following
DNA damage. Mol Cell 2000;6:649–659.
32. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human
Cdc25A in response to DNA damage. Science 2000;288:1425–1429.
33. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle
checkpoint determinant following irradiation. Proc Natl Acad Sci U S A
1992;89:7491–7495.
34. Xu B, Kim ST, Lim DS, et al. Two molecularly distinct G(2)/M checkpoints
are induced by ionizing irradiation. Mol Cell Biol 2002;22:
1049–1059.
35. Marples B, Wouters BG, Joiner MC. An association between the radiation-
induced arrest of G2-phase cells and low-dose hyper-radiosensitivity:
a plausible underlying mechanism? Radiat Res 2003;160:38–45.
36. Passalaris TM, Benanti JA, Gewin L, et al. The G(2) checkpoint is maintained
by redundant pathways. Mol Cell Biol 1999;19:5872–5881.
37. Kato JY, Matsuoka M, Strom DK, et al. Regulation of cyclin D-dependent
kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol
1994;14:2713–2721.
38. Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D
to the retinoblastoma gene product (pRb) and pRb phosphorylation by
the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331–342.
39. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta
regulates cyclin D1 proteolysis and subcellular localization. Genes Dev
1998;12:3499–3511.
40. Guo Y, Yang K, Harwalkar J, et al. Phosphorylation of cyclin D1 at
Thr 286 during S phase leads to its proteasomal degradation and allows
efficient DNA synthesis. Oncogene 2005;24:2599–2612.
41. Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein
required for cell cycle progression in G1. Genes Dev 1993;7:812–821.
42. Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential
mediator of apoptotic neuronal cell death. Embo J 1996;15:46–54.
43. Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, et al. Role
of cyclin D1 cytoplasmic sequestration in the survival of postmitotic
neurons. Oncogene 2003;22:8723–8730.
44. Bienvenu F, Gascan H, Coqueret O. Cyclin D1 represses STAT3
activation through a Cdk4-independent mechanism. J Biol Chem
2001;276:16840–16847.
45. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements
control the androgen-dependent proliferation of prostatic carcinoma
cells. J Biol Chem 1998;273:20213–20222.
46. Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with
the androgen receptor and inhibit its transcriptional transactivation
ability. Cancer Res 1999;59:2297–2301.
47. Qin C, Burghardt R, Smith R, et al. Peroxisome proliferator-activated
receptor gamma agonists induce proteasome-dependent degradation of
cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.
Cancer Res 2003;63:958–964.
48. Zwijsen RM, Buckle RS, Hijmans EM, et al. Ligand-independent recruitment
of steroid receptor coactivators to estrogen receptor by cyclin
D1. Genes Dev 1998;12:3488–3498.
49. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a
bcl1-linked candidate oncogene. Nature 1991;350:512–515.
50. van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in
invasive breast cancer. Correlations and prognostic value. Am J Pathol
1997;150:705–711.
51. Caputi M, Groeger AM, Esposito V, et al. Prognostic role of cyclin D1
in lung cancer. Relationship to proliferating cell nuclear antigen. Am J
Respir Cell Mol Biol 1999;20:746–750.
52. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 overexpression
in bronchial epithelia of patients with lung cancer is associated with
smoking and predicts survival. J Clin Oncol 2003;21:2085–2093.
53. Anton RC, Coffey DM, Gondo MM, et al. The expression of cyclins
D1 and E in predicting short-term survival in squamous cell carcinoma
of the lung. Mod Pathol 2000;13:1167–1172.
54. Ikehara M, Oshita F, Ito H, et al. Expression of cyclin D1 but not of
cyclin E is an indicator of poor prognosis in small adenocarcinomas of
the lung. Oncol Rep 2003;10:137–139.
55. Yamanouchi H, Furihata M, Fujita J, et al. Expression of cyclin E and
cyclin D1 in non-small cell lung cancers. Lung Cancer 2001;31:3–8.
56. Lonardo F, Rusch V, Langenfeld J, et al. Overexpression of cyclins D1
and E is frequent in bronchial preneoplasia and precedes squamous cell
carcinoma development. Cancer Res 1999;59:2470–2476.
57. Brambilla E, Gazzeri S, Moro D, et al. Alterations of Rb pathway (Rbp16INK4-
cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res
1999;5:243–250.
58. Tominaga M, Sueoka N, Irie K, et al. Detection and discrimination of
preneoplastic and early stages of lung adenocarcinoma using hnRNP
B1 combined with the cell cycle-related markers p16, cyclin D1, and
Ki-67. Lung Cancer 2003;40:45–53.
59. Kurasono Y, Ito T, Kameda Y, et al. Expression of cyclin D1, retinoblastoma
gene protein, and p16 MTS1 protein in atypical adenomatous
hyperplasia and adenocarcinoma of the lung. An immunohistochemical
analysis. Virchows Arch 1998;432:207–215.
60. Bombi JA, Martinez A, Ramirez J, et al. Ultrastructural and molecular
heterogeneity in non-small cell lung carcinomas: study of 110 cases and
review of the literature. Ultrastruct Pathol 2002;26:211–218.
61. Volm M, Koomagi R. Association of cyclin D1 expression in lung cancer
and the smoking habits of patients. Cancer Lett 1999;141:147–150.
62. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia
with features of gigantism, tumorigenesis, and female sterility in
p27(Kip1)-deficient mice. Cell 1996;85:733–744.
63. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21
are components of multiple cell cycle kinase complexes. Mol Biol Cell
1993;4:897–906.
64. Winters ZE. P53 pathways involving G2 checkpoint regulators and the role
of their subcellular localisation. J R Coll Surg Edinb 2002;47:591–598.
65. Taylor WR, Stark GR. Regulation of the G2/M transition by p53.
Oncogene 2001;20:1803–1815.
66. Coqueret O. Linking cyclins to transcriptional control. Gene
2002;299:35–55.
67. Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle
and cell fate. Crit Rev Oral Biol Med 2002;13:453–464.
68. Blagosklonny MV. Are p27 and p21 cytoplasmic oncoproteins? Cell
Cycle 2002;1:391–393.
69. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/
Cip1/Sdi1): association with cell senescence and tumour-promoting
activities of stromal fibroblasts. Cancer Lett 2002;179:1–14.
70. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor
p21 in apoptosis. Mol Cancer Ther 2002;1:639–649.
71. Hayashi H, Miyamoto H, Ito T, et al. Analysis of p21Waf1/Cip1 expression
in normal, premalignant, and malignant cells during the development
of human lung adenocarcinoma. Am J Pathol 1997;151:461–470.
72. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor
for favorable prognosis in squamous cell carcinoma of the lung. Clin
Cancer Res 1997;3:1831–1835.
73. Takeshima Y, Yamasaki M, Nishisaka T, et al. p21WAF1/CIP1 expression
in primary lung adenocarcinomas: heterogeneous expression in
tumor tissues and correlation with p53 expression and proliferative
activities. Carcinogenesis 1998;19:1755–1761.
74. Vonlanthen S, Heighway J, Kappeler A, et al. p21 is associated with
cyclin D1, p16INK4a and pRb expression in resectable non-small cell
lung cancer. Int J Oncol 2000;16:951–957.
75. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression
in non-small-cell lung cancer. J Clin Oncol 2002;20:3865–3871.
76. Bennett WP, el-Deiry WS, Rush WL, et al. p21waf1/cip1 and transforming
growth factor beta 1 protein expression correlate with survival
in non-small cell lung cancer. Clin Cancer Res 1998;4:1499–1506.
77. Esposito V, Baldi A, Tonini G, et al. Analysis of cell cycle regulator
proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58–63.
78. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display
increased body size, multiple organ hyperplasia, retinal dysplasia,
and pituitary tumors. Cell 1996;85:707–720.
79. Hayashi H, Ogawa N, Ishiwa N, et al. High cyclin E and low p27/Kip1
expressions are potentially poor prognostic factors in lung adenocarcinoma
patients. Lung Cancer 2001;34:59–65.
80. Kang Y, Ozbun LL, Angdisen J, et al. Altered expression of G1/S
regulatory genes occurs early and frequently in lung carcinogenesis in
transforming growth factor-beta1 heterozygous mice. Carcinogenesis
2002;23:1217–1227.
81. Kawana H, Tamaru J, Tanaka T, et al. Role of p27Kip1 and
cyclin-dependent kinase 2 in the proliferation of non-small cell lung
cancer. Am J Pathol 1998;153:505–513.
82. Tsukamoto S, Sugio K, Sakada T, et al. Reduced expression of cell-cycle
regulator p27(Kip1) correlates with a shortened survival in non-small
cell lung cancer. Lung Cancer 2001;34:83–90.
83. Ishihara S, Minato K, Hoshino H, et al. The cyclin-dependent kinase
inhibitor p27 as a prognostic factor in advanced non-small cell lung
cancer: its immunohistochemical evaluation using biopsy specimens.
Lung Cancer 1999;26:187–194.
84. Tsoli E, Gorgoulis VG, Zacharatos P, et al. Low levels of p27 in association
with deregulated p53-pRb protein status enhance tumor proliferation
and chromosomal instability in non-small cell lung carcinomas.
Mol Med 2001;7:418–429.
85. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance
of p27KIP1 protein and ki-67 growth fraction in non-small cell lung
cancers. Clin Cancer Res 2000;6:4073–4081.
86. Oshita F, Kameda Y, Nishio K, et al. Increased expression levels of cyclin-
dependent kinase inhibitor p27 correlate with good responses to
platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep
2000;7:491–495.
87. Gandara DR, Lara PN, Lau DH, et al. Molecular-clinical correlative
studies in non-small cell lung cancer: application of a three-tiered approach.
Lung Cancer 2001;34(Suppl 3):S75–S80.
88. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle
control causing specific inhibition of cyclin D/CDK4. Nature
1993;366:704–707.
89. Parry D, Bates S, Mann DJ, et al. Lack of cyclin D-Cdk complexes
in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour
suppressor gene product. Embo J 1995;14:503–511.
90. Betticher DC, White GR, Vonlanthen S, et al. G1 control gene status is
frequently altered in resectable non-small cell lung cancer. Int J Cancer
1997;74:556–562.
91. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression
of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical
study. Int J Cancer 1996;65:442–445.
92. Tanaka H, Fujii Y, Hirabayashi H, et al. Disruption of the RB pathway
and cell-proliferative activity in non-small-cell lung cancers. Int J
Cancer 1998;79:111–115.
93. Kashiwabara K, Oyama T, Sano T, et al. Correlation between methylation
status of the p16/CDKN2 gene and the expression of p16 and
Rb proteins in primary non-small cell lung cancers. Int J Cancer
1998;79:215–220.
94. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of
molecular and immunohistochemical profiles of the Rb and p53 cell
cycle regulatory pathways in primary non-small cell lung carcinoma.
Clin Cancer Res 2005;11:232–241.
95. Leversha MA, Fielding P, Watson S, et al. Expression of p53, pRB, and
p16 in lung tumours: a validation study on tissue microarrays. J Pathol
2003;200:610–619.
96. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression.
Exp Cell Res 2001;264:42–55.
97. Geradts J, Wilentz RE, Roberts H. Immunohistochemical [corrected]
detection of the alternate INK4a-encoded tumor suppressor protein
p14(ARF) in archival human cancers and cell lines using commercial
antibodies: correlation with p16(INK4a) expression. Mod Pathol
2001;14:1162–1168.
98. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and
puzzles. Curr Opin Genet Dev 2003;13:77–83.
99. Gao N, Hu YD, Cao XY, et al. The exogenous wild-type p14ARF gene
induces growth arrest and promotes radiosensitivity in human lung
cancer cell lines. J Cancer Res Clin Oncol 2001;127:359–367.
100. Weber HO, Samuel T, Rauch P, et al. Human p14(ARF)-mediated cell
cycle arrest strictly depends on intact p53 signaling pathways. Oncogene
2002;21:3207–3212.
101. Eymin B, Gazzeri S, Brambilla C, et al. Mdm2 overexpression and
p14(ARF) inactivation are two mutually exclusive events in primary
human lung tumors. Oncogene 2002;21:2750–2761.
102. Sanchez-Cespedes M, Reed AL, Buta M, et al. Inactivation of the
INK4A/ARF locus frequently coexists with TP53 mutations in nonsmall
cell lung cancer. Oncogene 1999;18:5843–5849.
103. Park MJ, Shimizu K, Nakano T, et al. Pathogenetic and biologic significance
of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer
Genet Cytogenet 2003;141:5–13.
104. Tango Y, Fujiwara T, Itoshima T, et al. Adenovirus-mediated p14ARF
gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in
human cancer cells. Hum Gene Ther 2002;13:1373–1382.
105. Jarmalaite S, Kannio A, Anttila S, et al. Aberrant p16 promoter methylation
in smokers and former smokers with nonsmall cell lung cancer.
Int J Cancer 2003;106:913–918.
106. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene
encoding a p53-associated protein in human sarcomas. Nature
1992;358:80–83.
107. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53
protein correlates with a poor prognosis in human lung cancer. Cancer
Res 1992;52:4828–4831.
108. Fornace AJ Jr, Nebert DW, Hollander MC, et al. Mammalian genes
coordinately regulated by growth arrest signals and DNA-damaging
agents. Mol Cell Biol 1989;9:4196–4203.
109. Puisieux A, Lim S, Groopman J, et al. Selective targeting of p53 gene
mutational hotspots in human cancers by etiologically defined carcinogens.
Cancer Res 1991;51:6185–6189.
110. Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent
kinases controls DNA replication by interaction with PCNA.
Nature 1994;369:574–578.
111. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation
of bax expression by p53 but not TGF beta 1: a paradigm for
distinct apoptotic pathways. Oncogene 1994;9:1791–1798.
112. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging
patterns from divergent signals. Genes Dev 1998;12:2973–2983.
113. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of
p53 lead to dominant-negative inhibition of wild-type p53 function.
Proc Natl Acad Sci U S A 2002;99:2948–2953.
114. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of
the K-ras oncogene causes early onset lung cancer in mice. Nature
2001;410:1111–1116.
115. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung
cancer by somatic inactivation of both Trp53 and Rb1 in a conditional
mouse model. Cancer Cell 2003;4:181–189.
116. Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer:
role of biomarkers. Eur Respir J Suppl 2003;39:S36–S44.
117. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor
suppressor gene alterations and clinicopathological features in resected
lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625–634.
118. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung
cancers reflect the primary mutagenic signature of DNA-damage by
tobacco smoke. Carcinogenesis 2001;22:367–374.
119. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53
tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Cancer Res 1994;54:4855–4878.
120. Pollan M, Varela G, Torres A, et al. Clinical value of p53, c-erbB-2,
CEA and CA125 regarding relapse, metastasis and death in resectable
non-small cell lung cancer. Int J Cancer 2003;107:781–790.
121. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic
substaging in 244 stage I non-small-cell lung cancer patients:
clinical implications. J Clin Oncol 1998;16:2468–2477.
122. Osaki T, Oyama T, Inoue M, et al. Molecular biological markers and
micrometastasis in resected non-small-cell lung cancer. Prognostic implications.
Jpn J Thorac Cardiovasc Surg 2001;49:545–551.
123. Zereu M, Vinholes JJ, Zettler CG. p53 and Bcl-2 protein expression
and its relationship with prognosis in small-cell lung cancer. Clin Lung
Cancer 2003;4:298–302.
124. Geradts J, Fong KM, Zimmerman PV, et al. Correlation of abnormal
RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other
genetic abnormalities, and clinical features in 103 primary non-small
cell lung cancers. Clin Cancer Res 1999;5:791–800.
125. Cheng YL, Lee SC, Harn HJ, et al. Prognostic prediction of the immunohistochemical
expression of p53 and p16 in resected non-small
cell lung cancer. Eur J Cardiothorac Surg 2003;23:221–228.
126. Wang Y, Zhang Z, Kastens E, et al. Mice with alterations in both p53
and Ink4a/Arf display a striking increase in lung tumor multiplicity
and progression: differential chemopreventive effect of budesonide in
wild-type and mutant A/J mice. Cancer Res 2003;63:4389–4395.
127. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity.
Oncogene 2003;22:7486–7495.
128. Senderowicz AM, Sausville EA. Preclinical and clinical development
of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:
376–387.
129. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-
dependent kinase inhibitor flavopiridol in patients with previously
untreated stage IV non-small cell lung cancer. Clin Cancer Res
2001;7:1590–1599.
130. Mason KA, Hunter NR, Raju U, et al. Flavopiridol increases therapeutic
ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Int J Rad Oncol Biol Phys 2004;59:1181–1189.
131. Nguyen VN, Mirejovsky P, Mirejovsky T, et al. Expression of cyclin
D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance
and comparison with p53 and bcl-2. Acta Histochem 2000;102:
323–338.
132. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases
and cdk inhibitors: implications in cell cycle control and cancer.
Crit Rev Eukaryot Gene Expr 1995;5:127–156.
133. Harper JW, Elledge SJ. Cdk inhibitors in development and cancer.
Curr Opin Genet Dev 1996;6:56–64.
134. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed
cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl
Acad Sci U S A 1999;96:4325–4329.
135. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1
by transcriptional repression in MCF-7 human breast carcinoma cells
induced by flavopiridol. Cancer Res 1999;59:4634–4641.
136. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, et
al. Structural basis for specificity and potency of a flavonoid inhibitor
of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A
1996;93:2735–2740.
137. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with
reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J
Natl Cancer Inst 1992;84:1736–1740.
138. Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of
CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res
Commun 1994;201:589–595.
139. Worland PJ, Kaur G, Stetler-Stevenson M, et al. Alteration of the phosphorylation
state of p34cdc2 kinase by the flavone L86-8275 in breast
carcinoma cells. Correlation with decreased H1 kinase activity. Biochem
Pharmacol 1993;46:1831–1840.
140. Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1
arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4
in human breast carcinoma cells. Cancer Res 1996;56:2973–2978.
141. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective
antitumor activity in vitro and activity in vivo for prostate carcinoma
cells. Clin Cancer Res 1997;3:273–279.
142. Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC
649890), a new kinase inhibitor for tumor therapy. Int J Oncol
1996;9:1143–1168.
143. Litz J, Carlson P, Warshamana-Greene GS, et al. Flavopiridol potently
induces small cell lung cancer apoptosis during S phase in a manner
that involves early mitochondrial dysfunction. Clin Cancer Res
2003;9:4586–4594.
144. Shapiro GI, Koestner DA, Matranga CB, et al. Flavopiridol induces
cell cycle arrest and p53-independent apoptosis in non-small cell lung
cancer cell lines. Clin Cancer Res 1999;5:2925–2938.
145. Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb,
p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their
clinical significance. J Pathol 1999;188:351–360.
146. Mishina T, Dosaka-Akita H, Kinoshita I, et al. Cyclin D1 expression in
non-small-cell lung cancers: its association with altered p53 expression, cell
proliferation and clinical outcome. Br J Cancer 1999;80:1289–1295.
147. Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins,
cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma.
Int J Cancer 1998;79:294–299.
148. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpression is an
indicator of poor prognosis in resectable non-small cell lung cancer. Br
J Cancer 1999;81:127–132.
149. Gugger M, Kappeler A, Vonlanthen S, et al. Alterations of cell cycle
regulators are less frequent in advanced non-small cell lung cancer than
in resectable tumours. Lung Cancer 2001;33:229–239.
150. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol
Hematol 2001;38:139–170.
151. Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin
Pharmacol 2003;3:362–370.
152. Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors
alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Drug Resist Updat 2003;6:15–26.
153. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via
initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes
apoptosis-reluctant cells to tumor necrosis factor. Cancer Res
2004;64:3653–3660.
154. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces
cell death in noncycling A549 human lung carcinoma cells. Cancer Res
1996;56:4856–4861.
155. Hayon IL, Haupt Y. p53: an internal investigation. Cell Cycle
2002;1:111–116.
156. Raju U, Nakata E, Mason KA, et al. Flavopiridol, a cyclin-dependent
kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Cancer Res 2003;63:3263–3267.
157. Chien M, Astumian M, Liebowitz D, et al. In vitro evaluation of flavopiridol,
a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother
Pharmacol 1999;44:81–87.
158. Sato S, Kajiyama Y, Sugano M, et al. Flavopiridol as a radio-sensitizer
for esophageal cancer cell lines. Dis Esophagus 2004;17:338–344.
159. Camphausen K, Brady KJ, Burgan WE, et al. Flavopiridol enhances
human tumor cell radiosensitivity and prolongs expression of gamma-
H2AX foci. Mol Cancer Ther 2004;3:409–416.
160. Jung C, Motwani M, Kortmansky J, et al. The cyclin-dependent
kinase inhibitor flavopiridol potentiates gamma-irradiation-induced
apoptosis in colon and gastric cancer cells. Clin Cancer Res
2003;9:6052–6061.
161. Newcomb EW, Lymberis SC, Lukyanov Y, et al. Radiation sensitivity
of GL261 murine glioma model and enhanced radiation response by
flavopiridol. Cell Cycle 2006;5:93–99.
162. Raju U, Ariga H, Koto M, et al. Improvement of esophageal adenocarcinoma
cell and xenograft responses to radiation by targeting cyclindependent
kinases. Radiother Oncol 2006;80:185–191.
163. Kim JC, Saha D, Cao Q, et al. Enhancement of radiation effects by
combined docetaxel and flavopiridol treatment in lung cancer cells.
Radiother Oncol 2004;71:213–221.
164. McAleer MF, Duffy KT, Davidson WR, et al. Antisense inhibition of
cyclin D1 expression is equivalent to flavopiridol for radiosensitization
of zebrafish embryos. Int J Radiat Oncol Biol Phys 2006;66:546–551.
165. Seynaeve CM, Stetler-Stevenson M, Sebers S, et al. Cell cycle arrest and
growth inhibition by the protein kinase antagonist UCN-01 in human
breast carcinoma cells. Cancer Res 1993;53:2081–2086.
166. Hui ZG, Li YX, Yang WZ, et al. [Abrogation effect of UCN-01 on
radiation-induced G2 phase arrest of tumor cells and its mechanism.].
Ai Zheng 2005;24:1–6.
167. Playle LC, Hicks DJ, Qualtrough D, et al. Abrogation of the radiation-
induced G2 checkpoint by the staurosporine derivative UCN-01
is associated with radiosensitisation in a subset of colorectal tumour cell
lines. Br J Cancer 2002;87:352–358.
168. Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent
7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint
kinase hChk1. Cancer Res 2000;60:2108–2112.
169. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the
Cdc25C regulatory pathways are targets of the anticancer agent UCN-
01. J Biol Chem 2000;275:5600–5605.
170. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint
kinase 1/cell division cycle 25A pathway abrogates ionizing
radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A
2002;99:14795–14800.
171. Xiao Z, Chen Z, Gunasekera AH, et al. Chk1 mediates S and G2
arrests through Cdc25A degradation in response to DNA-damaging
agents. J Biol Chem 2003;278:21767–21773.
172. Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1
checkpoint pathway in mammals: linkage of DNA damage to Cdk
regulation through Cdc25. Science 1997;277:1497–1501.
173. Mailand N, Podtelejnikov AV, Groth A, et al. Regulation of G(2)/M
events by Cdc25A through phosphorylation-dependent modulation of
its stability. Embo J 2002;21:5911–5920.
174. Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects
in cancer cells lacking p53 function. Cell Cycle 2002;1:362–368.
175. Xiao HH, Makeyev Y, Butler J, et al. 7-Hydroxystaurosporine (UCN-
01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation
in lung cancer cell lines. Radiat Res 2002;158:84–93.
176. Mack PC, Jones AA, Gustafsson MH, et al. Enhancement of radiation
cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat
Res 2004;162:623–634.
177. Lara PN Jr, Mack PC, Synold T, et al. The cyclin-dependent kinase
inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California
cancer consortium phase I pharmacokinetic and molecular correlative
trial. Clin Cancer Res 2005;11:4444–4450.
178. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the
cyclin -dependent kinase inhibitor and protein kinase C inhibitor
7-hydroxystaurosporine in combination with Fluorouracil in patients
with advanced solid tumors. J Clin Oncol 2005;23:1875–1884.
179. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in
combination with topotecan in patients with advanced solid cancers:
a Princess Margaret Hospital Phase II Consortium study. Ann Oncol
2006;17:334–340.
180. Mitchison TJ. Microtubule dynamics and kinetochore function in mitosis.
Annu Rev Cell Biol 1988;4:527–549.
181. Altmann KH. Microtubule-stabilizing agents: a growing class of important
anticancer drugs. Curr Opin Chem Biol 2001;5:424–431.
182. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation.
Proc Natl Acad Sci U S A 1995;92:4507–4511.
183. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule
integrity. Cancer Res 1997;57:229–233.
184. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation
and death of prostate cancer cells. Cancer Res 1996;56:
1253–1255.
185. Hei TK, Piao CQ, Geard CR, et al. Taxol and ionizing radiation: interaction
and mechanisms. Int J Radiat Oncol Biol Phys 1994;29:267–271.
186. Rowinsky EK. The development and clinical utility of the taxane class of
antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353–374.
187. Mason K, Staab A, Hunter N, et al. Enhancement of tumor radioresponse
by docetaxel: involvement of immune system. Int J Oncol
2001;18:599–606.
188. Creane M, Seymour CB, Colucci S, et al. Radiobiological effects of
docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol
1999;75:731–737.
189. Zhao J, Kim JE, Reed E, et al. Molecular mechanism of antitumor
activity of taxanes in lung cancer (Review). Int J Oncol 2005;27:
247–256.
190. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med
1995;332:1004–1014.
191. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities
encountered with paclitaxel (Taxol). Semin Oncol 1993;20:1–15.
192. Geney R, Ungureanu M, Li D, et al. Overcoming multidrug resistance
in taxane chemotherapy. Clin Chem Lab Med 2002;40:918–925.
193. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of
microtubule-stabilizing agents with a taxol-like mechanism of action.
Cancer Res 1995;55:2325–2333.
194. Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures—
a new class of microtubule inhibitors with potent in vivo antitumor
activity. Biochim Biophys Acta 2000;1470:M79–M91.
195. Kim JC, Kim JS, Saha D, et al. Potential radiation-sensitizing effect
of semisynthetic epothilone B in human lung cancer cells. Radiother
Oncol 2003;68:305–313.
196. Andrews PD, Knatko E, Moore WJ, et al. Mitotic mechanics: the auroras
come into view. Curr Opin Cell Biol 2003;15:672–683
197. Carmena M, Earnshaw WC. The cellular geography of aurora kinases.
Nat Rev Mol Cell Biol 2003;4:842–854.
198. Brown JR, Koretke KK, Birkeland ML, et al. Evolutionary relationships
of Aurora kinases: implications for model organism studies and
the development of anti-cancer drugs. BMC Evol Biol 2004;4:39.
199. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the
fidelity of early and late mitotic events in HeLa cells. J Biol Chem
2003;278:51786–51795.
200. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation
and tumorigenesis. Cancer Metastasis Rev 2003;22:451–464.
201. Du J, Hannon GJ. Suppression of p160ROCK bypasses cell cycle
arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci U S A
2004;101:8975–8980.
202. Cazales M, Schmitt E, Montembault E, et al. CDC25B phosphorylation
by Aurora-A occurs at the G2/M transition and is inhibited by
DNA damage. Cell Cycle 2005;4:1233–1238.
203. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora
kinase a suppresses tumor growth and enhances the taxane chemosensitivity
in human pancreatic cancer cells. Cancer Res 2005;65:2899–2905.
204. Wang XX, Liu R, Jin SQ, et al. Overexpression of Aurora-A kinase
promotes tumor cell proliferation and inhibits apoptosis in esophageal
squamous cell carcinoma cell line. Cell Res 2006;16:356–366.
205. Tao Y, Zhang P, Frascogna V, et al. Enhancement of radiation response
by inhibition of Aurora-A kinase using siRNA or a selective Aurora
kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer
2007;97(12):1664–1672.
206. Guan Z, Wang XR, Zhu XF, et al. Aurora-A, a negative prognostic
marker, increases migration and decreases radiosensitivity in cancer
cells. Cancer Res 2007;67:10436–10444.
207. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and
aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
Int J Radiat Oncol Biol Phys 2007;67:1519–1525.
208. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome
alignment with anaphase by targeting BubR1, Mad2, and Cenp-
E to kinetochores. J Cell Biol 2003;161:267–280.
209. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat
Rev Cancer 2004;4:927–936.
210. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and
selective small-molecule inhibitor of the Aurora kinases, suppresses
tumor growth in vivo. Nat Med 2004;10:262–267.
211. Hwang M, Perez CA, Moretti L, et al. The mTOR signaling network:
insights from its role during embryonic development. Curr Med Chem
2008;15:1192–1208.
212. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer.
Trends Mol Med 2005;11:353–361.
213. De Virgilio C, Loewith R. Cell growth control: little eukaryotes make
big contributions. Oncogene 2006;25:6392–6415.
214. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of
tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414–5422.
215. Albert JM, Kim KW, Cao C, et al. Targeting the Akt/mammalian target
of rapamycin pathway for radiosensitization of breast cancer. Mol
Cancer Ther 2006;5:1183–1189.
216. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target
of rapamycin or apoptotic pathway induces autophagy and radiosensitizes
PTEN null prostate cancer cells. Cancer Res 2006;66:10040–10047.
217. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor
suppression. Cell 2000;100:387–390.
218. Freeman D, Lesche R, Kertesz N, et al. Genetic background controls
tumor development in PTEN-deficient mice. Cancer Res 2006;66:
6492–6496.
219. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a
candidate tumour suppressor gene, MMAC1, at chromosome
10q23.3 that is mutated in multiple advanced cancers. Nat Genet
1997;15:356–362.
220. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular
transformation induced by the oncoproteins P3k and Akt. Proc Natl
Acad Sci U S A 2001;98:136–141.
221. Kim KW, Hwang M, Moretti L, et al. Autophagy upregulation by inhibitors
of caspase-3 and mTOR enhances radiotherapy in a mouse
model of lung cancer. Autophagy 2008;4:659–668.
222. Kim KW, Mutter RW, Cao C, et al. Autophagy for cancer therapy
through inhibition of pro-apoptotic proteins and mammalian target of
rapamycin signaling. J Biol Chem 2006;281:36883–36890.
223. Jaboin JJ, Shinohara ET, Moretti L, et al. The role of mTOR inhibition
in augmenting radiation induced autophagy. Technol Cancer Res Treat
2007;6:443–447.
224. Forouzesh B, Buckner J, Adjei A, et al. Phase I, bioavailability, and
pharmacokinetic study of oral dosage of CCl-779 administered to patients
with advanced solid malignancies. Eur J Cancer 2002;38:S54.
225. Pandya KJ, Levy DE, Hidalgo M, et al. A randomized, phase II ECOG
trial of two dose levels of temsirolimus (CCI-779) in patients with extensive
stage small cell lung cancer in remission after induction chemotherapy.
A preliminary report. J Clin Oncol 2005;23:S622.
226. Baselga J, Burris H, Judson I, et al. Molecular pharmacodynamic
(MPD) phase I study with serial tumor and skin biopsies of the oral
mTOR inhibitor Everolimus (E, RAD001) at different doses and
schedules in patients (pts) with advanced solid tumors. Ejc Supplements
2005;3:419–419.
227. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian
target of rapamycin inhibitor deforolimus (AP23573; MK-8669)
administered intravenously daily for 5 days every 2 weeks to patients
with advanced malignancies. J Clin Oncol 2008;26:361–367.
228. Molina JR, Mandrekar SJ, Rowland K, et al. A phase IINCCTG “window
of opportunity front-line” study of the mTOR inhibitor, CCI-
779 (temsirolimus) given as a single agent in patients with advanced
NSCLC. J Thorac Oncol 2007;2:S413–S413.
229. O’Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and
pharmacodynamic study of the oral mammalian target of rapamycin
inhibitor everolimus in patients with advanced solid tumors. J Clin
Oncol 2008;26:1588–1595.
230. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular
pharmacodynamic (MPD) evaluation of dose and schedule of
the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with
advanced solid tumors. J Clin Oncol 2005;23:193S–193S.
231. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189
mRNA isoform expression specifically correlates with tumor angiogenesis,
patient survival, and postoperative relapse in non-small-cell lung
cancer. J Clin Oncol 2001;19:432–441.
232. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth
factor expression in stage I non-small cell lung cancer correlates with
neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72–79.
233. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31,
CD34, and CD105 expression and tumour vessel invasion after radical surgery
for IB-IIA non-small cell lung cancer. J Clin Pathol 2004;57:591–597.
234. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth
factor is associated with neovascularization and influences progression
of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861–865.
235. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and
overexpression of vascular endothelial growth factor are associated with
unfavourable prognosis in operated small cell lung carcinoma. Br J
Cancer 2002;86:558–563.
236. Houchen CW, George RJ, Sturmoski MA, et al. FGF-2 enhances intestinal
stem cell survival and its expression is induced after radiation
injury. Am J Physiol 1999;276:G249–G258.
237. Thornton SC, Walsh BJ, Bennett S, et al. Both in vitro and in vivo irradiation
are associated with induction of macrophage-derived fibroblast
growth factors. Clin Exp Immunol 1996;103:67–73.
238. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular
endothelial growth factor stress response increases the antitumor effects
of ionizing radiation. Cancer Res 1999;59:3374–3378.
239. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to
radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:
1155–1159.
240. Chung YL, Jian JJ, Cheng SH, et al. Sublethal irradiation induces
vascular endothelial growth factor and promotes growth of hepatoma
cells: implications for radiotherapy of hepatocellular carcinoma. Clin
Cancer Res 2006;12:2706–2715.
241. Sonveaux P, Brouet A, Havaux X, et al. Irradiation-induced angiogenesis
through the up-regulation of the nitric oxide pathway: implications
for tumor radiotherapy. Cancer Res 2003;63:1012–1019.
242. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway
in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
243. Liu W, Ahmad SA, Reinmuth N, et al. Endothelial cell survival and
apoptosis in the tumor vasculature. Apoptosis 2000;5:323–328.
244. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor
response to antiangiogenic therapy. Science 2002;295:1526–1528.
245. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab,
an anti-vascular endothelial growth factor antibody, for metastatic
renal cancer. N Engl J Med 2003;349:427–434.
246. Moffat BA, Chen M, Kariaapper MS, et al. Inhibition of vascular
endothelial growth factor (VEGF)-A causes a paradoxical increase in
tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res
2006;12:1525–1532.
247. Steel G, Peckham M. Exploitable mechanisms in combined radiotherapy-
chemotherapy: the concept of additivity. Int J Radiat Oncol Biol
Phys 1979;5:85–91.
248. Shibuya M. Structure and dual function of vascular endothelial growth
factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001;33:409–420.
249. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D
(VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and
VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548–553.
250. Ferrara N. VEGF: an update on biological and therapeutic aspects.
Curr Opin Biotechnol 2000;11:617–624.
251. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth
factor treatment augments tumor radiation response under normoxic
or hypoxic conditions. Cancer Res 2000;60:5565–5570.
252. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth
factor receptor-2-blocking antibody potentiates radiation-induced longterm
control of human tumor xenografts. Cancer Res 2001;61:39–44.
253. Ning S, Laird D, Cherrington JM, et al. The antiangiogenic agents
SU5416 and SU6668 increase the antitumor effects of fractionated
irradiation. Radiat Res 2002;157:45–51.
254. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor
PTK787/ZK222584 [correction of ZK222548] combined with ionizing
radiation on endothelial cells and tumour growth. Br J Cancer
2001;85:2010–2016.
255. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial
growth factor receptor signaling leads to reversal of tumor
resistance to radiotherapy. Cancer Res 2001;61:2413–2419.
256. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible
factor 1. Crit Rev Oncol Hematol 2006;59:15–26.
257. Jain RK. Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 2005;307:58–62.
258. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization
by VEGFR2 blockade governs brain tumor response to radiation: role
of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer
Cell 2004;6:553–563.
259. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent,
orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase
inhibitor for the treatment of cancer. Cancer Res 2005;65:4389–4400.
260. Cao C, Albert JM, Geng L, et al. Vascular endothelial growth factor
tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in
mouse models of lung cancer. Cancer Res 2006;66:11409–11415.
261. Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent inhibitor
of vascular endothelial growth factor signaling, combined with radiotherapy:
schedule-dependent enhancement of antitumor activity. Clin
Cancer Res 2004;10:8587–8593.
262. Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase
inhibition increases the tumor response to single and fractionated dose
radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:836–841.
263. Lu B, Geng L, Musiek A, et al. Broad spectrum receptor tyrosine kinase
inhibitor, SU6668, sensitizes radiation via targeting survival pathway of
vascular endothelium. Int J Radiat Oncol Biol Phys 2004;58:844–850.
264. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies
in non-small cell lung cancer: a winner strategy? Curr Opin Oncol
2007;19:98–102.
265. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance
therapy prevents tumor regrowth after fractionated irradiation of murine
tumor models. Cancer Res 2003;63:4009–4016.
266. Riesterer O, Honer M, Jochum W, et al. Ionizing radiation antagonizes
tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res
2006;12:3518–3524.
267. Zips D, Hessel F, Krause M, et al. Impact of adjuvant inhibition of
vascular endothelial growth factor receptor tyrosine kinases on tumor
growth delay and local tumor control after fractionated irradiation in
human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol
Phys 2005;61:908–914.
268. Kermani P, Leclerc G, Martel R, et al. Effect of ionizing radiation on
thymidine uptake, differentiation, and VEGFR2 receptor expression in
endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys
2001;50:213–220.
269. Huamani J, Willey C, Thotala D, et al. Differential efficacy of combined
therapy with radiation and AEE788 in high and low EGFR–expressing
androgen-independent prostate tumor models. Int J Radiat Oncol Biol
Phys 2008;71:237–246.
270. Yazlovitskaya EM, Linkous AG, Thotala DK, et al. Cytosolic phospholipase
A(2) regulates viability of irradiated vascular endothelium. Cell
Death Differ 2008;15(10):1641–1653.
271. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression
of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
J Biol Chem 1990;265:16737–16740.
272. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase
2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Cancer Res 1998;58:3761–3764.
273. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2
in human lung carcinoma. Cancer Res 1998;58:4997–5001.
274. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated
cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Clin Cancer Res 1999;5:1001–1005.
275. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a
marker of poor prognosis in stage I non-small cell lung cancer. Clin
Cancer Res 2001;7:861–867.
276. Davis TW, O’Neal JM, Pagel MD, et al. Synergy between celecoxib
and radiotherapy results from inhibition of cyclooxygenase-2-derived
prostaglandin E2, a survival factor for tumor and associated vasculature.
Cancer Res 2004;64:279–285.
277. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor
activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306–1311.
278. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu
Rev Med 2002;53:35–57.
279. Furuta Y, Hunter N, Barkley T Jr, et al. Increase in radioresponse of murine
tumors by treatment with indomethacin. Cancer Res 1988;48:3008–3013.
280. Teicher B, Bump E, Palayoor S. Signal transduction inhibitors as modifiers
of radiation therapy in human prostate carcinoma xenografts.
Radiat Oncol Invest 1996;4:221–230.
281. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor
radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:
1326–1331.
282. Gallo O. Re: enhancement of tumor response to gamma-radiation
by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst
2000;92:346–347.
283. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor,
NS-398, enhances the effect of radiation in vitro and in vivo
preferentially on the cells that express cyclooxygenase-2. Clin Cancer
Res 2001;7:2998–3005.
284. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to
gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl
Cancer Inst 1999;91:1501–1504.
285. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor
cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Clin Cancer Res 2000;6:2513–2520.
286. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers
of tumor radioresponse. Semin Radiat Oncol 2001;11:290–299.
287. Furuta Y, Hall ER, Sanduja S, et al. Prostaglandin production by murine
tumors as a predictor for therapeutic response to indomethacin.
Cancer Res 1988;48:3002–3007.
288. Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib,
a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent
cell cycle regulation on human cancer cells expressing differential COX-2
levels. Cancer Res 2005;65:9501–9509.
289. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-
2. Cancer J 2001;7 Suppl 3:S144–150.
290. Dittmann KH, Mayer C, Ohneseit PA, et al. Celecoxib induced tumor
cell radiosensitization by inhibiting radiation induced nuclear EGFR
transport and DNA-repair: a Cox-2 independent mechanism. Int J
Radiat Oncol Biol Phys 2008;70(1):203–212.
291. Chakraborti S. Phospholipase A(2) isoforms: a perspective. Cell Signal
2003;15:637–665.
292. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and
physiological role of cytosolic phospholipase A2. Biol Pharm Bull
2004;27:1168–1173.
293. Prokazova NV, Zvezdina ND, Korotaeva AA. Effect of lysophosphatidylcholine
on transmembrane signal transduction. Biochemistry (Mosc)
1998;63:31–37.
294. Fujita Y, Yoshizumi M, Izawa Y, et al. Transactivation of fetal liver kinase-
1/kinase-insert domain-containing receptor by lysophosphatidylcholine
induces vascular endothelial cell proliferation. Endocrinology
2006;147:1377–1385.
295. Murugesan G, Sandhya Rani MR, Gerber CE, et al. Lysophosphatidylcholine
regulates human microvascular endothelial cell expression
of chemokines. J Mol Cell Cardiol 2003;35:1375–1384.
296. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally
induces growth factor gene expression in cultured human endothelial
cells. J Clin Invest 1994;93:907–911.
297. Kita T, Kume N, Ochi H, et al. Induction of endothelial plateletderived
growth factor-B-chain and intercellular adhesion molecule-1
by lysophosphatidylcholine. Ann N Y Acad Sci 1997;811:70–75.
298. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear
leukocyte adhesion molecule during atherogenesis. Science
1991;251:788–791.
299. Murohara T, Scalia R, Lefer AM. Lysophosphatidylcholine promotes
P-selectin expression in platelets and endothelial cells. Possible
involvement of protein kinase C activation and its inhibition by nitric
oxide donors. Circ Res 1996;78:780–789.
300. Tan J, Geng L, Yazlovitskaya EM, et al. Protein kinase B/Akt-dependent
phosphorylation of glycogen synthase kinase-3beta in irradiated
vascular endothelium. Cancer Res 2006;66:2320–2327.
301. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling:
inside-out and outside-in. Mol Cancer Ther 2007;6:789–801.
302. Edwards E, Geng L, Tan J, et al. Phosphatidylinositol 3-kinase/Akt
signaling in the response of vascular endothelium to ionizing radiation.
Cancer Res 2002;62:4671–4677.
303. Dent P, Yacoub A, Fisher PB, et al. MAPK pathways in radiation responses.
Oncogene 2003;22:5885–5896.
304. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase
D activity leading to tumor cell growth and motility by lysophosphatidic
acid production. J Cell Biol 2002;158:227–233.
305. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid
in cancer. Nat Rev Cancer 2003;3:582–591.
306. Nam SW, Clair T, Campo CK, et al. Autotaxin (ATX), a potent tumor
motogen, augments invasive and metastatic potential of ras-transformed
cells. Oncogene 2000;19:241–247.
307. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing
motogen, is an angiogenic factor. Cancer Res 2001;61:6938–6944.
308. Klominek J, Robert KH, Bergh J, et al. Production of a motility factor
by a newly established lung adenocarcinoma cell line. Anticancer Res
1998;18:759–767.
309. Yang Y, Mou L, Liu N, et al. Autotaxin expression in non-small-cell
lung cancer. Am J Respir Cell Mol Biol 1999;21:216–222.
310. Kolesnick RN. Sphingomyelinase action inhibits phorbol ester-induced
differentiation of human promyelocytic leukemic (HL-60) cells. J Biol
Chem 1989;264:7617–7623.
311. Kolesnick RN, Clegg S. 1,2-Diacylglycerols, but not phorbol esters,
activate a potential inhibitory pathway for protein kinase C in GH3
pituitary cells. Evidence for involvement of a sphingomyelinase. J Biol
Chem 1988;263:6534–6537.
312. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via
ceramide. Biochem J 1998;335(Pt 3):465–480.
313. Okazaki T, Bielawska A, Bell RM, et al. Role of ceramide as a lipid
mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation.
J Biol Chem 1990;265:15823–15831.
314. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation
acts on cellular membranes to generate ceramide and initiate apoptosis.
J Exp Med 1994;180:525–535.
315. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid
second messengers. Curr Opin Cell Biol 1996;8:159–167.
316. Merrill AH, Jr., Schmelz EM, Dillehay DL, et al. Sphingolipids—the
enigmatic lipid class: biochemistry, physiology, and pathophysiology.
Toxicol Appl Pharmacol 1997;142:208–225.
317. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism:
from modular to integrative signaling. Biochemistry 2001;40:
4893–4903.
318. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary
lesion initiating intestinal radiation damage in mice. Science
2001;293:293–297.
319. Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced
apoptosis in Burkitt’s lymphoma cells is associated with defective ceramide
signaling. Cancer Res 1997;57:3600–3605.
320. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-
deficient human lymphoblasts and mice are defective in radiationinduced
apoptosis. Cell 1996;86:189–199.
321. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin
signal transduction pathway mediates apoptosis for tumor necrosis factor,
Fas, and ionizing radiation. Biochem Cell Biol 1994;72:471–474.
322. Raines MA, Kolesnick RN, Golde DW. Sphingomyelinase and ceramide
activate mitogen-activated protein kinase in myeloid HL-60
cells. J Biol Chem 1993;268:14572–14575.
323. Huwiler A, Brunner J, Hummel R, et al. Ceramide-binding and activation
defines protein kinase c-Raf as a ceramide-activated protein kinase.
Proc Natl Acad Sci U S A 1996;93:6959–6963.
324. Verheij M, Ruiter GA, Zerp SF, et al. The role of the stress-activated
protein kinase (SAPK/JNK) signaling pathway in radiation-induced
apoptosis. Radiother Oncol 1998;47:225–232.
325. Chen YR, Wang X, Templeton D, et al. The role of c-Jun N-terminal
kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation.
Duration of JNK activation may determine cell death and proliferation.
J Biol Chem 1996;271:31929–31936.
326. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase
(JNK)—from inflammation to development. Curr Opin Cell Biol
1998;10:205–219.
327. Li CM, Park JH, Simonaro CM, et al. Insertional mutagenesis of the
mouse acid ceramidase gene leads to early embryonic lethality in homozygotes
and progressive lipid storage disease in heterozygotes. Genomics
2002;79:218–224.
328. Kolesnick R. The therapeutic potential of modulating the ceramide/
sphingomyelin pathway. J Clin Invest 2002;110:3–8.
329. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer
pathogenesis and treatment. Nat Rev Cancer 2004;4:604–616.
330. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-
1-phosphate antibody as a potential therapeutic in reducing
growth, invasion, and angiogenesis in multiple tumor lineages. Cancer
Cell 2006;9:225–238.
331. Chmura SJ, Nodzenski E, Beckett MA, et al. Loss of ceramide production
confers resistance to radiation-induced apoptosis. Cancer Res
1997;57:1270–1275.
332. Chmura SJ, Nodzenski E, Kharbanda S, et al. Down-regulation of ceramide
production abrogates ionizing radiation-induced cytochrome c
release and apoptosis. Mol Pharmacol 2000;57:792–796.
333. Garzotto M, Haimovitz-Friedman A, Liao WC, et al. Reversal of radiation
resistance in LNCaP cells by targeting apoptosis through ceramide
synthase. Cancer Res 1999;59:5194–5201.
334. Kimura K, Markowski M, Edsall LC, et al. Role of ceramide in mediating
apoptosis of irradiated LNCaP prostate cancer cells. Cell Death
Differ 2003;10:240–248.
335. Nava VE, Cuvillier O, Edsall LC, et al. Sphingosine enhances apoptosis of
radiation-resistant prostate cancer cells. Cancer Res 2000;60:4468–4474.
336. Chmura SJ, Mauceri HJ, Advani S, et al. Decreasing the apoptotic
threshold of tumor cells through protein kinase C inhibition and
sphingomyelinase activation increases tumor killing by ionizing radiation.
Cancer Res 1997;57:4340–4347.
337. Lin X, Fuks Z, Kolesnick R. Ceramide mediates radiation-induced
death of endothelium. Crit Care Med 2000;28:N87–N93.
338. Ree AH, Bratland A, Nome RV, et al. Inhibitory targeting of checkpoint
kinase signaling overrides radiation-induced cell cycle gene regulation:
a therapeutic strategy in tumor cell radiosensitization? Radiother
Oncol 2004;72:305–310.
339. Hui ZG, Li YX, Yang WZ, et al. [Abrogation of radiation-induced G2
arrest and radiosensitization by 7-hydroxystaurosporine (UCN-01) in
human nasopharyngeal carcinoma cell line]. Ai Zheng 2003;22:6–10.
340. Schuuring J, Bussink J, Bernsen HJ, et al. Irradiation combined with
SU5416: microvascular changes and growth delay in a human xenograft
glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005;61:529–534.
341. Lund EL, Olsen MW, Lipson KE, et al. Improved effect of an antiangiogenic
tyrosine kinase inhibitor (SU5416) by combinations with
fractionated radiotherapy or low molecular weight heparin. Neoplasia
2003;5:155–160.
342. Gong H, Pottgen C, Stuben G, et al. Arginine deiminase and other
antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation
by irradiation. Int J Cancer 2003;106:723–728.
343. Griffin RJ, Williams BW, Wild R, et al. Simultaneous inhibition of the
receptor kinase activity of vascular endothelial, fibroblast, and plateletderived
growth factors suppresses tumor growth and enhances tumor
radiation response. Cancer Res 2002;62:1702–1706.
344. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both
pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
J Clin Invest 2003;111:1287–1295.
345. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase
inhibitor SU11248 impedes endothelial cell migration, tubule formation,
and blood vessel formation in vivo, but has little effect on existing
tumor vessels. Angiogenesis 2004;7:225–233.
346. Plastaras JP, Kim SH, Liu YY, et al. Cell cycle dependent and schedule-
dependent antitumor effects of sorafenib combined with radiation.
Cancer Res 2007;67:9443–9454.
347. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of
weekly single-agent patupilone in patients with advanced solid tumors.
J Clin Oncol 2005;23:9120–9129.
348. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular
endothelial growth factor receptor-2-blocking antibody plus fractionated
radiotherapy on murine mammary tumors. Cancer Res 2004;64:
5712–5719.
349. Li J, Huang S, Armstrong EA, et al. Angiogenesis and radiation response
modulation after vascular endothelial growth factor receptor-2
(VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005;62:1477–1485.
350. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis
inhibitors anginex and Avastin improves therapeutic outcome
via vessel normalization. Clin Cancer Res 2007;13:3395–3402.
351. Hoang T, Huang S, Armstrong E. Enhancement of radiation response
in upper aero-digestive tract tumors with bevacizumab (Avastin). Lung
Cancer 2005;49(Suppl 2):S370.
352. Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial
growth factor enhances endothelial cell survival and tumor radioresistance.
Cancer J 2002;8:47–54.
353. Damiano V, Melisi D, Bianco C, et al. Cooperative antitumor effect
of multitargeted kinase inhibitor ZD6474 and ionizing radiation in
glioblastoma. Clin Cancer Res 2005;11:5639–5644.
354. Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell
radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme:
mechanistic considerations. Int J Radiat Oncol Biol Phys 2002;54:
886–894.
355. Kuipers GK, Slotman BJ, Wedekind LE, et al. Radiosensitization of
human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent
on COX-2 expression and dependent on the COX-2 inhibitor
and sequence of administration. Int J Radiat Biol 2007;83:677–685.
356. Wachsberger PR, Burd R, Marero N, et al. Effect of the tumor vasculardamaging
agent, ZD6126, on the radioresponse of U87 glioblastoma.
Clin Cancer Res 2005;11:835–842.
357. Raben D, Bianco C, Damiano V, et al. Antitumor activity of ZD6126,
a novel vascular-targeting agent, is enhanced when combined with
ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor,
and potentiates the effects of radiation in a human non-small cell
lung cancer xenograft model. Mol Cancer Ther 2004;3:977–983.
358. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy
combined with combretastatin a4 phosphate in human
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:
1375–1380.
359. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium
phosphate: a vascular targeting agent that improves that improves the
anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
Int J Radiat Oncol Biol Phys 2001;51:1018–1024.
360. Dings RP, Williams BW, Song CW, et al. Anginex synergizes with radiation
therapy to inhibit tumor growth by radiosensitizing endothelial
cells. Int J Cancer 2005;115:312–319.
361. Griscelli F, Li H, Cheong C, et al. Combined effects of radiotherapy
and angiostatin gene therapy in glioma tumor model. Proc Natl Acad
Sci U S A 2000;97:6698–6703.
362. Kumar P, Benedict R, Urzua F, et al. Combination treatment significantly
enhances the efficacy of antitumor therapy by preferentially targeting
angiogenesis. Lab Invest 2005;85:756–767.
363. Geng L, Tan J, Himmelfarb E, et al. A specific antagonist of the
p110delta catalytic component of phosphatidylinositol 3'-kinase,
IC486068, enhances radiation-induced tumor vascular destruction.
Cancer Res 2004;64:4893–4899.